$-0.01 EPS Expected for StarTek, Inc. (SRT); Ritter Pharmaceuticals (RTTR) SI Decreased By 0.66%

February 15, 2018 - By Darrin Black

Analysts expect StarTek, Inc. (NYSE:SRT) to report $-0.01 EPS on February, 20.They anticipate $0.08 EPS change or 114.29% from last quarter’s $0.07 EPS. After having $-0.07 EPS previously, StarTek, Inc.’s analysts see -85.71% EPS growth. The stock decreased 0.63% or $0.07 during the last trading session, reaching $11. About 72,841 shares traded. StarTek, Inc. (NYSE:SRT) has risen 150.65% since February 15, 2017 and is uptrending. It has outperformed by 133.95% the S&P500.

Ritter Pharmaceuticals Incorporated (NASDAQ:RTTR) had a decrease of 0.66% in short interest. RTTR’s SI was 1.21M shares in February as released by FINRA. Its down 0.66% from 1.22 million shares previously. With 468,900 avg volume, 3 days are for Ritter Pharmaceuticals Incorporated (NASDAQ:RTTR)’s short sellers to cover RTTR’s short positions. The SI to Ritter Pharmaceuticals Incorporated’s float is 16.11%. The stock increased 6.00% or $0.0181 during the last trading session, reaching $0.3199. About 153,109 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since February 15, 2017 and is downtrending. It has underperformed by 72.91% the S&P500.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $15.84 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The companyÂ’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. Roth Capital maintained Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) rating on Monday, June 5. Roth Capital has “Buy” rating and $3.5000 target. Rodman & Renshaw initiated it with “Buy” rating and $7 target in Wednesday, January 4 report. Maxim Group initiated the stock with “Buy” rating in Thursday, April 14 report. The rating was maintained by Chardan Capital Markets on Tuesday, October 25 with “Buy”. As per Wednesday, July 5, the company rating was maintained by Maxim Group. As per Wednesday, December 2, the company rating was initiated by Chardan Capital Markets. The firm has “Hold” rating by Maxim Group given on Friday, August 4. The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has “Buy” rating given on Monday, October 23 by H.C. Wainwright.

StarTek, Inc. provides business process outsourcing services in the United States, Canada, Honduras, Jamaica, and the Philippines. The company has market cap of $177.57 million. It operates in three divisions: Domestic, Nearshore, and Offshore. It has a 82.71 P/E ratio. The company??s service offerings include customer care, sales support, inbound sales, complex order processing, accounts receivable management, technical and product support, up-sell and cross-sell opportunities, customer intelligence analytics, and other industry-specific processes.

Among 2 analysts covering StarTek (NYSE:SRT), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. StarTek had 6 analyst reports since November 8, 2016 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, October 3 by Robert W. Baird. On Tuesday, November 8 the stock rating was upgraded by Lake Street to “Buy”. Robert W. Baird maintained the shares of SRT in report on Wednesday, January 24 with “Hold” rating. As per Wednesday, February 22, the company rating was maintained by Lake Street. Robert W. Baird maintained the shares of SRT in report on Friday, September 1 with “Hold” rating.

Investors sentiment decreased to 1.41 in 2017 Q3. Its down 0.88, from 2.29 in 2017Q2. It dived, as 6 investors sold StarTek, Inc. shares while 16 reduced holdings. 11 funds opened positions while 20 raised stakes. 6.96 million shares or 3.30% less from 7.20 million shares in 2017Q2 were reported. Eam Invsts Limited Co reported 183,761 shares. Renaissance Techs Ltd Liability Com holds 781,881 shares. The Massachusetts-based State Street has invested 0% in StarTek, Inc. (NYSE:SRT). Bridgeway Capital Mgmt owns 156,000 shares for 0.02% of their portfolio. The Georgia-based Invesco has invested 0% in StarTek, Inc. (NYSE:SRT). Martingale Asset Mgmt L P has invested 0.01% in StarTek, Inc. (NYSE:SRT). Oppenheimer Asset Inc holds 0% or 1,411 shares in its portfolio. Us Bancorp De, a Minnesota-based fund reported 45 shares. Connor Clark Lunn Inv Mngmt Limited holds 0% or 15,725 shares. Moreover, Heartland Advsrs has 0.83% invested in StarTek, Inc. (NYSE:SRT) for 1.09M shares. Prelude Capital Mngmt Limited Liability Corp holds 0% or 623 shares. Geode Mgmt Ltd Company has invested 0% in StarTek, Inc. (NYSE:SRT). California Public Employees Retirement System stated it has 0% of its portfolio in StarTek, Inc. (NYSE:SRT). 4,418 are held by Tower Capital Limited Liability Corporation (Trc). Valley National Advisers owns 0% invested in StarTek, Inc. (NYSE:SRT) for 50 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: